Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study

dc.contributor.authorToribio-Vázquez, C.
dc.contributor.authorGómez Rivas, J.
dc.contributor.authorAmigo, F.
dc.contributor.authorCarrión, D.M.
dc.contributor.authorYebes, Á.
dc.contributor.authorAlonso-Bartolomé, M.
dc.contributor.authorAyllon, H.
dc.date.accessioned2025-05-10T15:21:49Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractIntroduction: Malignant tumors of the urinary tract are associated with high morbidity and mortality, and their prevalence can vary worldwide. Recently, the IDENTIFY study has published results on the prevalence of urinary tract cancer at a global level. This study evaluates the prevalence of cancer within the Spanish cohort of the IDENTIFY study to determine whether the published results can be extrapolated to our population. Patients and methods: An analysis of the data from the Spanish cohort of patients in the IDENTIFY study was performed. This is a prospective cohort of patients referred to secondary care with suspected cancer, predominantly due to hematuria. Patients were recruited between December 2017 and December 2018. Results: A total of 706 patients from 9 Spanish centers were analyzed. Of these, 277 (39.2%) were diagnosed with cancer: 259 (36.7%) bladder cancer, 10 (1.4%) upper tract urothelial carcinoma, 9 (1.2%) renal cancer and 5 (0.7%) prostate cancer. Increasing age (OR: 1.05; 95% CI: 1.03-1.06; P<.001), visible hematuria (VH) OR: 2.19; 95% CI: 1.13-4.24; P=.02)and smoking (ex-smokers: OR: 2.11; 95% CI: 1.30-3.40; P=.002); (smokers: OR: 2.36; 95% CI: 1.40-3.95; P=.001) were associated with higher probability of bladder cancer. Conclusion: This study highlights the risk of bladder cancer in patients with VH and smoking habits. Bladder cancer presented the highest prevalence; higher than the prevalence reported in previous series and presented in the IDENTIFY study. Future work should evaluate other associated factors that allow us to create cancer prediction models to improve the detection of cancer in our patients. © 2023 AEU
dc.identifier.doi10.1016/j.acuro.2023.06.004
dc.identifier.endpage237
dc.identifier.issn0210-4806
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85166311934
dc.identifier.scopusqualityQ3
dc.identifier.startpage228
dc.identifier.urihttps://doi.org/10.1016/j.acuro.2023.06.004
dc.identifier.urihttps://hdl.handle.net/20.500.14730/6163
dc.identifier.volume48
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofActas Urologicas Espanolas
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250302
dc.subjectBladder cancer; Hematuria; Renal cancer; Risk factors; Urinary tract cancer; Urothelial carcinoma
dc.titlePrevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study
dc.title.alternativePrevalencia del cáncer del tracto urinario. Análisis de la cohorte española del estudio IDENTIFY
dc.typeArticle

Dosyalar